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Power calculations were not used to determine the sample size. The study sample consisted of 125 patients with AAAs who underwent either open or EV repairs: 61 in the EV group, 24 in the RP group, and 40 in the TA group. The age distribution of patients was not reported. The distribution of patients in the EV group in terms of type of endovascular procedure was as follows: 30 had tube endografts, 24 bifurcated endovascular grafts, and 7 underwent aortouniiliac and femorofemoral reconstruction.
Study design
This was a retrospective cohort study, carried out in a single centre. The duration of the follow-up was 30 days after the operation or until hospital discharge. Loss to follow-up was not to reported.
Analysis of effectiveness
The principle used in the analysis of effectiveness was intention to treat. The clinical outcomes were operative factors (total operating time, total blood loss, and any intraoperative complications requiring a change in operative plan), postoperative morbidity occurring within the first 30 days or before hospital discharge (pneumonia, postoperative bleeding, myocardial infarction, renal failure, graft thrombosis, respiratory failure, and wound complications), and mortality (defined as death occurring within 30 days of the procedure or during the same hospital admission). The patient groups were comparable in terms of preoperative risk factors except for hyperlipidemia, which was significantly higher in the RP group. The most frequent anatomic reasons for excluding patients from the EV group were the absence of a proximal neck, presence of significant iliac aneurysmal disease, and occlusive disease.
Effectiveness results
The EV group had a mean (SD) operating time of 283 (92) minutes versus 296 (115) for the RP group and 298 (122) for the TA groups, (NS). The operating time was significantly longer for the subgroup of EV patients who underwent aortouniiliac and femorofemoral repair (372 mins.) compared with those who had the EV tube or bifurcated repairs. The mean blood loss for the three study groups was 300 mL (range: 100 -1300 mL) for the EV group, 700 mL (range: 200 -3000 mL) for the RP group, and 786 mL (range: 150 -3000 mL) for the TA group. The difference between the TA and RP groups was not significant while the EV group had a significantly lower estimated blood loss, (p<0.05). Six cases of perigraft leaks which were persistent at 30 days (9.6%) were observed in the EV group. The EV group also had six cases (9.6%) of conversions to surgical repair. The percentage of cases of respiratory failure was 0% in the EV group versus 4.2% in the RP group and 12.5% in the TA group (statistically significantly higher in the TA group, p<0.05). The percentage of incidence of wound complications was 0% in the EV group, 12.5% in the RP group, and 2.5% in the TA group (TA versus RP versus EV, p<0.05). The corresponding values for incidence of arrhythmias were 0% for the EV group, 12.5% for the RP group, and 10% for the TA group, (TA and RP versus EV, p<0.05). The three groups were similar in terms of all other postoperative (30-day) morbidity. The EV group had a 30-day mortality rate of 0% versus 4.2% for the RP group and 2.5% for the TA group, (p>0.3).
Clinical conclusions
The mortality rate in these series was not significantly different across the TA, PR, and EV approaches. EV AAA repair significantly shortens hospital stay and ICU use and has a lower morbidity rate.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis, and only separate clinical outcomes were reported. methods in the context in question. You, as a database user, should consider whether these are widely used health technologies in your own setting.
Validity of estimate of measure of effectiveness
As the authors acknowledged, the internal validity of the effectiveness results can not be reasonably guaranteed given the retrospective nature of the study design and the relatively small sample size. The study groups were found to be comparable in terms of preoperative risk factors, except for hyperlipidemia, which was significantly higher in the RP group. The surgical group and the EV group were different in terms of anatomic features. It is not clear whether the study sample was representative of the study population given the fact that the study patients were also participants in a strictly monitored, Food and Drug Administration-approved protocol.
Validity of estimate of measure of benefit
The authors did not derive a measure of health benefit. The economic analysis was therefore a cost-consequences design.
Validity of estimate of costs
Some quantities (operating room and hospital stay) were reported separately from the costs. Adequate details of the methods of cost estimation were given. The exclusion of the costs of preoperation evaluations may have adversely affected the internal validity of the cost results. Statistical analysis was performed on some components of the resource use data and cost data. The price year was not specified. The potential impacts of the EV approach on indirect costs (lost productivity) were not investigated.
Other issues
In view of the retrospective nature of the study design and its small sample size and lack of sensitivity analysis, some degree of caution may need to be exercised in the interpretation of the study results, as acknowledged by the authors. The issue of generalisability to other settings or countries was not addressed. Some comparisons were made with other studies. The study sample consisted of patients who were participants in a strictly monitored Food and Drug Administration-approved protocol, and this seems to be reflected in the authors' comments. The age distribution of the study patients was not reported. Costs and benefits could be synthesised by performing cost-effectiveness analysis, which would involve selecting a single benefit measure. The authors conjectured that differences in surgical skills may have introduced bias into the results since the TA approach was distributed among the institution's surgeons while the RP approach was performed mostly by one surgeon. However, it was reported that no differences were noted in the results of the TA group by the study team, suggesting comparability in surgical skill. It was acknowledged that the EV group in this study represented the experience with one particular device (EndoVascular Technologies, Menlo Park, Calif), which may or may not be comparable with other devices under investigations.
Implications of the study
The eventual long-term outcome and cost of care of patients in the EV group awaits further analysis, which was in progress at the time of the study. EV AAA repair is unlikely to save money for the health care system and its use is likely to be driven by patient and physician preference, because of a significant decrease in morbidity rate and length of hospital stay.
